Ingo Bauerfeind

7.0k total citations · 1 hit paper
103 papers, 4.4k citations indexed

About

Ingo Bauerfeind is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ingo Bauerfeind has authored 103 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 55 papers in Cancer Research and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ingo Bauerfeind's work include Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (26 papers) and Cancer Treatment and Pharmacology (20 papers). Ingo Bauerfeind is often cited by papers focused on Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (26 papers) and Cancer Treatment and Pharmacology (20 papers). Ingo Bauerfeind collaborates with scholars based in Germany, Switzerland and United States. Ingo Bauerfeind's co-authors include Michael Untch, Gϋnter von Minckwitz, Annette Lebeau, Valentina Nekljudova, Tanja Fehm, Kerstin Hermelink, Karin Münzel, Barbara Fleige, G Helms and Sabine Schmatloch and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Ingo Bauerfeind

99 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

2013 928 citations Thorsten Kuehn, Ingo Bauerfeind et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ingo Bauerfeind Germany	29	2.2k	2.2k	1.1k	1.0k	692	103	4.4k
Shin‐Cheh Chen Taiwan	35	2.9k 1.3×	1.3k 0.6×	700 0.7×	1.8k 1.8×	1.1k 1.6×	128	4.9k
Louise Provencher Canada	31	3.2k 1.4×	1.8k 0.9×	803 0.7×	1.1k 1.1×	582 0.8×	110	4.8k
Michael P. Lux Germany	34	1.7k 0.8×	1.6k 0.7×	560 0.5×	1.3k 1.2×	460 0.7×	262	4.5k
Sherko Kümmel Germany	37	2.5k 1.1×	2.0k 0.9×	910 0.8×	814 0.8×	465 0.7×	227	5.0k
Joon Jeong South Korea	33	1.9k 0.9×	1.7k 0.8×	573 0.5×	677 0.6×	496 0.7×	274	4.0k
James Waisman United States	33	2.0k 0.9×	2.7k 1.2×	2.1k 1.9×	466 0.4×	1.1k 1.6×	100	4.6k
Chafika Mazouni France	30	2.3k 1.0×	2.5k 1.2×	877 0.8×	672 0.6×	688 1.0×	124	5.2k
Gary N. Schwartz United States	29	1.3k 0.6×	1.2k 0.5×	470 0.4×	1.0k 1.0×	305 0.4×	89	3.7k
I Taylor United Kingdom	38	2.0k 0.9×	1.4k 0.7×	1.2k 1.1×	920 0.9×	1.5k 2.2×	166	4.9k
Christian Menzel Germany	37	1.8k 0.8×	1.3k 0.6×	467 0.4×	620 0.6×	738 1.1×	100	4.6k

Countries citing papers authored by Ingo Bauerfeind

Since Specialization

Citations

This map shows the geographic impact of Ingo Bauerfeind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Bauerfeind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Bauerfeind more than expected).

Fields of papers citing papers by Ingo Bauerfeind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingo Bauerfeind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Bauerfeind. The network helps show where Ingo Bauerfeind may publish in the future.

Co-authorship network of co-authors of Ingo Bauerfeind

This figure shows the co-authorship network connecting the top 25 collaborators of Ingo Bauerfeind. A scholar is included among the top collaborators of Ingo Bauerfeind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingo Bauerfeind. Ingo Bauerfeind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braun, Michael, Nadia Harbeck, Sven Mahner, et al.. (2021). Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Annals of Oncology. 32(11). 1410–1424. 46 indexed citations

Kolberg, Hans‐Christian, Thorsten Kühn, Ingo Bauerfeind, et al.. (2020). Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer patients: A transSENTINA analysis.. Journal of Clinical Oncology. 38(15_suppl). 567–567.

Hermelink, Kerstin, Markus Bühner, Karin Münzel, et al.. (2017). Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients. JNCI Journal of the National Cancer Institute. 109(10). 69 indexed citations

Halfter, Kathrin, Oliver Hoffmann, Nina Ditsch, et al.. (2016). Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. Journal of Translational Medicine. 14(1). 112–112. 43 indexed citations

Bauerfeind, Ingo, et al.. (2016). eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy. JMIR Cancer. 2(2). e14–e14. 9 indexed citations

Wuerstlein, Rachel, Karl Sotlar, Oleg Gluz, et al.. (2016). The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. Current Medical Research and Opinion. 32(7). 1217–1224. 22 indexed citations

Stieber, P, Dorothea Nagel, Volker Heinemann, et al.. (2015). Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. Clinica Chimica Acta. 448. 228–231. 53 indexed citations

Kolben, Thomas, et al.. (2014). Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) – Results from the Munich Cancer Registry. The Breast. 24(1). 24–31. 11 indexed citations

Minckwitz, Gϋnter von, Mahdi Rezai, Peter A. Fasching, et al.. (2013). Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro). Annals of Oncology. 25(1). 81–89. 51 indexed citations

10.

Thiel, Falk C., Michael Schrauder, Peter A. Fasching, et al.. (2012). Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. Breast Cancer Research and Treatment. 135(3). 811–820. 15 indexed citations

11.

Bauerfeind, Ingo, Dirk Elling, & Volker Heinemann. (2010). Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer. Breast Care. 5(1). 13–15. 9 indexed citations

12.

Untch, Michael, Sibylle Loibl, Peter A. Fasching, et al.. (2008). Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements. 6(7). 47–47. 16 indexed citations

13.

Bauerfeind, Ingo, et al.. (2008). A multicentric analysis and an introduction of a German prospective study to evaluate the value of sentinel node excision after neoadjuvant chemotherapy. European Journal of Cancer Supplements. 6(7). 148–148. 2 indexed citations

14.

Bauerfeind, Ingo, Steffen Kahlert, Isabelle Himsl, et al.. (2007). The risk of non-sentinel metastases in primary breast cancer.. PubMed. 27(4A). 1929–32. 2 indexed citations

15.

Schmidt, Gerwin P., Andrea Baur‐Melnyk, Alexander Haug, et al.. (2007). Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3T compared to FDG–PET–CT. European Journal of Radiology. 65(1). 47–58. 105 indexed citations

16.

Rack, Brigitte, Bernd Gerber, Ingo Bauerfeind, et al.. (2006). Pregnancy-Associated Breast Cancer – Special Features in Diagnosis and Treatment. Oncology Research and Treatment. 29(3). 107–112. 5 indexed citations

17.

Vodermaier, Andrea, Ingo Bauerfeind, & Carolin Nestle-Krämling. (2006). Prophylaktische Chirurgie bei Brust- und Eierstockkrebsrisiko. Ein Überblick über die internationale Forschungsliteratur zu Einstellungen, Inanspruchnahmeverhalten und Lebensqualität. Geburtshilfe und Frauenheilkunde. 66(11). 1035–1049. 2 indexed citations

18.

Mylonas, Ioannis, Udo Jeschke, Christiane Kunert‐Keil, et al.. (2006). Glycodelin A is expressed differentially in normal human endometrial tissue throughout the menstrual cycle as assessed by immunohistochemistry and in situ hybridization. Fertility and Sterility. 86(5). 1488–1497. 24 indexed citations

19.

Konecny, Gottfried E., Y. Gloria Meng, Michael Untch, et al.. (2004). Association between HER-2/ neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients. Clinical Cancer Research. 10(5). 1706–1716. 230 indexed citations

20.

Bauerfeind, Ingo, et al.. (2004). Neoadjuvante Chemotherapie bei Mammakarzinom. Gyn�kologisch-geburtshilfliche Rundschau. 44(2). 92–101. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact